Understanding how APE1 protein helps in DNA damage response in cancer cells
Official title: Roles and regulations of APE1 in ATR signaling
Funded at University of North Carolina Charlotte · NIH-11127888 · Data updated 2026-11-12
This study is looking at how a protein called APE1 helps cancer cells fix their damaged DNA, which could lead to new ways to treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $342,569 |
| NIH project number | 1R01CA291546-01A1 |
| Project ID | NIH-11127888 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who may benefit from improved DNA repair therapies.
✕Less likely to help
Patients with non-cancerous conditions or those not experiencing DNA damage-related issues may not receive benefits from this research.
What this research studies
This research investigates the role of the APE1 protein in the cellular response to DNA damage, particularly in cancer cells. It focuses on how APE1 interacts with single-strand DNA gaps and activates ATR signaling, which is crucial for maintaining genomic stability. The study employs biochemical techniques and cellular models to explore the mechanisms by which APE1 influences DNA repair processes and cell viability in the context of cancer. By understanding these processes, the research aims to uncover potential therapeutic targets for cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing cancer therapies by targeting DNA repair mechanisms.
How similar studies have gone: Previous research has shown promising results in targeting DNA repair mechanisms in cancer, suggesting that this approach could be beneficial.
Where this research is happening
-
University of North Carolina Charlotte
Charlotte, United States Active
Researchers
- Principal investigator: Yan, Shan — University of North Carolina Charlotte
- Study coordinator: Yan, Shan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.